Stocks Overview

LAST PRICE
2.4400
TODAY'S CHANGE (%)
0.0000 (0.0000%)

Bid / Lots
2.0700/ 1
Ask / Lots
2.6000/ 2
Open / Previous Close
0.0000 / 2.4400
Day Range
---
52 Week Range
Low 1.1200
High 2.8399
Volume
---
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Wednesday's close: 2.68
Time	Volume	GRTX
09:32 ET	8577	2.7
09:34 ET	1036	2.6905
09:36 ET	4434	2.74
09:38 ET	6492	2.75
09:39 ET	31519	2.8
09:41 ET	4590	2.789
09:43 ET	1385	2.805
09:45 ET	6862	2.8304
09:48 ET	9143	2.81
09:50 ET	4628	2.79
09:52 ET	19076	2.76
09:54 ET	7881	2.71
09:56 ET	4603	2.72
09:57 ET	23379	2.65
09:59 ET	2540	2.6504
10:01 ET	3736	2.67
10:03 ET	7902	2.62
10:06 ET	7023	2.61
10:08 ET	3044	2.62
10:10 ET	8029	2.635
10:12 ET	1800	2.62
10:14 ET	31972	2.58
10:15 ET	4346	2.6
10:17 ET	376	2.58
10:19 ET	1357	2.57
10:21 ET	6928	2.605
10:24 ET	3926	2.63
10:26 ET	5175	2.62
10:28 ET	200	2.625
10:30 ET	600	2.62
10:32 ET	1675	2.62
10:33 ET	24779	2.61
10:35 ET	6200	2.615
10:37 ET	1700	2.615
10:39 ET	2254	2.61
10:42 ET	1435	2.6101
10:44 ET	500	2.615
10:46 ET	6406	2.625
10:48 ET	1593	2.63
10:50 ET	1207	2.63
10:51 ET	4679	2.63
10:53 ET	350	2.6201
10:55 ET	1000	2.62
10:57 ET	500	2.6201
11:00 ET	500	2.625
11:02 ET	100	2.625
11:04 ET	1103	2.615
11:06 ET	4500	2.61
11:09 ET	100	2.61
11:11 ET	500	2.615
11:13 ET	17478	2.5992
11:18 ET	10700	2.59
11:20 ET	6636	2.585
11:24 ET	500	2.58
11:29 ET	584	2.58
11:31 ET	7977	2.5501
11:33 ET	2453	2.55
11:36 ET	1882	2.5699
11:38 ET	2772	2.575
11:40 ET	100	2.565
11:42 ET	1500	2.58
11:44 ET	200	2.565
11:45 ET	200	2.5785
11:47 ET	510	2.5756
11:49 ET	2301	2.5784
11:51 ET	16024	2.59
11:54 ET	3200	2.58
11:56 ET	100	2.575
11:58 ET	300	2.565
12:00 ET	100	2.55
12:02 ET	5100	2.5516
12:03 ET	806	2.565
12:05 ET	2415	2.58
12:07 ET	1059	2.56
12:09 ET	1336	2.56
12:12 ET	910	2.5867
12:14 ET	1349	2.58
12:16 ET	1124	2.58
12:18 ET	2174	2.5601
12:20 ET	170	2.56
12:23 ET	990	2.561
12:27 ET	495	2.57
12:32 ET	266	2.56
12:34 ET	800	2.5691
12:36 ET	100	2.565
12:38 ET	16600	2.56
12:39 ET	100	2.56
12:41 ET	362	2.56
12:43 ET	1850	2.56
12:45 ET	100	2.55
12:54 ET	1200	2.56
12:56 ET	3867	2.56
12:59 ET	7370	2.5612
01:06 ET	425	2.5613
01:08 ET	165	2.56
01:10 ET	3300	2.565
01:12 ET	2138	2.57
01:14 ET	300	2.57
01:15 ET	1359	2.57
01:17 ET	658	2.56
01:19 ET	698	2.56
01:24 ET	1000	2.5501
01:26 ET	4100	2.5509
01:28 ET	800	2.5681
01:30 ET	1529	2.56
01:33 ET	600	2.5627
01:35 ET	800	2.57
01:37 ET	170	2.55
01:39 ET	100	2.56
01:42 ET	500	2.5689
01:46 ET	23688	2.53
01:48 ET	12674	2.51
01:50 ET	28136	2.495
01:51 ET	4756	2.52
01:53 ET	5400	2.5387
01:55 ET	1000	2.523
01:57 ET	1000	2.5101
02:00 ET	170	2.51
02:04 ET	1500	2.5248
02:08 ET	200	2.52
02:09 ET	667	2.51
02:13 ET	2200	2.51
02:15 ET	650	2.515
02:18 ET	3390	2.52
02:20 ET	500	2.5101
02:22 ET	1448	2.5101
02:24 ET	1965	2.51
02:26 ET	250	2.515
02:27 ET	800	2.5216
02:29 ET	500	2.5135
02:31 ET	863	2.52
02:33 ET	427	2.525
02:40 ET	900	2.53
02:42 ET	100	2.51
02:44 ET	465	2.51
02:45 ET	1000	2.5024
02:47 ET	1000	2.5173
02:51 ET	368	2.5
02:54 ET	557	2.5117
02:56 ET	200	2.5127
03:03 ET	168	2.5
03:05 ET	200	2.51
03:14 ET	500	2.505
03:16 ET	1190	2.51
03:18 ET	367	2.5
03:25 ET	307	2.5
03:27 ET	264	2.505
03:30 ET	1200	2.5001
03:32 ET	500	2.515
03:34 ET	2267	2.5104
03:36 ET	2896	2.52
03:38 ET	338	2.52
03:39 ET	376	2.51
03:41 ET	507	2.51
03:43 ET	1929	2.52
03:45 ET	2259	2.52
03:48 ET	11101	2.5
03:50 ET	100	2.5
03:52 ET	21456	2.485
03:54 ET	54732	2.44
03:56 ET	21220	2.44
03:57 ET	26673	2.44
03:59 ET	26811	2.44

Data delayed at least 15 minutes.

Mar 22, 2023
- --HC Wainwright Adjusts Galera Therapeutics Price Target to $6 From $10, Maintains Buy Rating, from 7:48AM ET on Wednesday Mar 22, 2023 by MT Newswires
  7:48AM ET on Wednesday Mar 22, 2023 by MT Newswires
Mar 14, 2023
- Insider Buy: Galera Therapeutics, from 8:43AM ET on Tuesday Mar 14, 2023 by MT Newswires
  8:43AM ET on Tuesday Mar 14, 2023 by MT Newswires
Mar 10, 2023
- BRIEF-Galera To Present Supplemental Analysis Of Phase 3 Trial At European Congress On Head And Neck Oncology, from 9:07AM ET on Friday Mar 10, 2023 by Thomson Reuters
  9:07AM ET on Friday Mar 10, 2023 by Thomson Reuters
- Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology, from 7:00AM ET on Friday Mar 10, 2023 by GlobeNewswire
  7:00AM ET on Friday Mar 10, 2023 by GlobeNewswire
Mar 8, 2023
- BRIEF-Galera Reports Fourth Quarter And 2022 Financial Results , from 7:41AM ET on Wednesday Mar 08, 2023 by Thomson Reuters
  7:41AM ET on Wednesday Mar 08, 2023 by Thomson Reuters

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesGRTX Galera Therapeutics Inc	104.5M	-1.1x	---
United StatesMNOV MediciNova Inc	105.4M	-7.5x	---
United StatesAURX Nuo Therapeutics Inc	103.5M	-29.4x	---
United StatesVXRT Vaxart Inc	102.6M	-0.9x	---
United StatesTLSA Tiziana Life Sciences Ltd	106.9M	-6.2x	---
United StatesCVM CEL-SCI Corp	101.5M	-2.7x	---
As of 2023-03-31

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a pipeline of therapeutic candidates to transform radiotherapy in cancer. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic in development for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC) and for the reduction of esophagitis in patients with lung cancer. It has completed Phase III Reduction in Oral Mucositis with Avasopasem Manganese (ROMAN) trial of GC4419 for the reduction of radiotherapy-induced SOM in patients with locally advanced HNC. Its second dismutase mimetic product candidate, rucosopasem manganese (GC4711), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).

Contact Information

Headquarters: P.O. Box 134MALVERN, PA, United States 19355
Phone: 610-725-1500
Fax: 302-636-5454

Executives

Independent Chairman of the Board: Michael Powell
President, Chief Executive Officer, Director: J. Mel Sorensen
Chief Financial Officer, Secretary: Christopher Degnan
Chief Operating Officer: Robert Beardsley
Chief Legal & Compliance Officer and Secretary: Jennifer Stacey

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

Fundamentals Table
Market Cap	$104.5M
Revenue (TTM)	$0.00
Shares Outstanding	42.8M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	1.78
EPS	$-2.30
Book Value	$-3.83
P/E Ratio	-1.1x
Price/Sales (TTM)	---
Price/Cash Flow (TTM)	---
Operating Margin	---

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Galera Therapeutics Inc
NASDAQ:GRTXUnited States

Search Criteria

Charts

Recent News

Mar 22, 2023

--HC Wainwright Adjusts Galera Therapeutics Price Target to $6 From $10, Maintains Buy Rating, from 7:48AM ET on Wednesday Mar 22, 2023 by MT Newswires

Mar 14, 2023

Insider Buy: Galera Therapeutics, from 8:43AM ET on Tuesday Mar 14, 2023 by MT Newswires

Mar 10, 2023

BRIEF-Galera To Present Supplemental Analysis Of Phase 3 Trial At European Congress On Head And Neck Oncology, from 9:07AM ET on Friday Mar 10, 2023 by Thomson Reuters

Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology, from 7:00AM ET on Friday Mar 10, 2023 by GlobeNewswire

Mar 8, 2023

BRIEF-Galera Reports Fourth Quarter And 2022 Financial Results , from 7:41AM ET on Wednesday Mar 08, 2023 by Thomson Reuters

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar